Japan-based Takeda Pharmaceutical Company, through its Indian subsidiary Takeda Biopharmaceuticals India, and Dr. Reddy’s Laboratories, have entered into a distribution agreement under which Dr. Reddy’s will promote and distribute Takeda’s dengue vaccine, QDENGA®, across India’s private market for pediatric and adult vaccination in India.
Subject to completion of applicable processes with local authorities, the vaccine is anticipated to become available in the first half of 2027.
The collaboration follows the approval of QDENGA’s marketing authorisation by India’s Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4-60 years. As India’s first approved dengue vaccine, the approval marks an important milestone in the country’s efforts to strengthen dengue prevention and management.
While inclusion in India’s public immunisation programme remains an important long-term ambition, private-market availability through Dr. Reddy’s will provide a pathway for eligible individuals to access the vaccine once it becomes available.
Through the collaboration, Takeda and Dr. Reddy’s will support healthcare-professional engagement, disease awareness, promotion and distribution of QDENGA across India’s private market for paediatric and adult vaccination, in accordance with applicable regulatory requirements.
